Media Contact:
Paula Flavin
Project/Marketing Manager
D: 816-912-2000
Email: info@felixvet.com

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Kansas City, Mo. — September 22, 2025 — Felixvet Inc. is proud to announce a recent FDA approval for Clindamycin Hydrochloride Tablets, an oral antibiotic approved for use in dogs to treat skin infections, abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains.

“With the approval of Clindamycin Hydrochloride Tablets, we’re expanding access to a trusted treatment option that veterinarians rely on for managing common yet potentially serious infections,” said Vince Palasota, President of North America at Felixvet. “This product reflects our ongoing commitment to quality, affordability and clinical relevance.”

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis and has demonstrated activity against a broad spectrum of aerobic and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens. It is especially effective for deep-seated infections, such as those in bone or dental tissues.

The tablets are available in 25 mg, 75 mg and 150 mg strengths and are dosed every 12 hours, with duration of treatment varying based on infection type, typically a few days for acute infections and up to 28 days for osteomyelitis.

“Clindamycin is a proven, versatile therapeutic, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories. 

For more information, contact info@felixvet.com.

About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.